McKesson beats, raises FY27 EPS outlook and highlights growth M&A

 

McKesson beats fiscal Q2 2027 with EPS $11.68, revenue $111.0B, raises FY27 EPS outlook and highlights growth M&A

• Q2 revenue grew 8% to $111B, with all four segments contributing to growth.
• Adjusted EPS rose 18% YoY to $11.68, aided by margin leverage and buybacks.
• FY27 adjusted EPS guidance raised to $45.60–$46.40, implying 17–19% growth.
• North American Pharmaceutical operating profit jumped 22%, driven by specialty and GLP-1 volumes.
• GLP-1 distribution revenue reached $16B, up 26% YoY and 8% sequentially.
• Oncology & Multispecialty revenue grew 24%, though operating profit fell ex prior-year gains.
• Medical-Surgical operating profit declined 10%, with mix headwinds in ambulatory care.
• Precision Medicine acquisition and Option Care stake deepen oncology, biopharma and home-infusion exposure.
• Main concern: sustainability of outsized North American Pharma growth amid GLP-1, biosimilar, and policy shifts.
• Strong quarter, driven by broad-based growth and operating leverage in North American Pharmaceutical.

https://finviz.com/stock?t=MCK&p=d